首页> 外文期刊>Hospital pharmacy. >Evaluation of Vancomycin Dosing in Patients With Cirrhosis: Beginning De Liver-ations about a New Nomogram
【24h】

Evaluation of Vancomycin Dosing in Patients With Cirrhosis: Beginning De Liver-ations about a New Nomogram

机译:肝硬化患者的万古霉素给药评价:开始肝脏关于新的探测图

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Reduced hepatic production of creatinine precursors in patients with decompensated cirrhosis leads to falsely low serum creatinine values. Therefore, when performing empiric dosing of vancomycin, an overestimation of creatinine clearance may result in significantly supratherapeutic vancomycin levels and increased risks of nephrotoxicity. Objective: The objective of the study is to evaluate vancomycin dosing requirements in patients with cirrhosis stratified by Child-Pugh Score, with subsequent comparison with doses that are recommended in the previously published and validated Kullar nomogram. Methods: A retrospective evaluation of patients with cirrhosis who received vancomycin for at least 3 full days and had at least I serum concentration drawn. Vancomycin daily dose and corresponding serum concentration were collected with patients stratified by Child-Pugh Score for comparison. Each patient had their vancomycin dose compared with the dose suggested by a published nomogram. Results: A total of 201 courses of vancomycin were followed. There were no significant differences between the Child-Pugh cohorts with respect to initial vancomycin dosing. There was also no significant difference in the median initial vancomycin trough concentration between the 3 cohorts (Child-Pugh A: 13.7 ug/mL [interquartile range, IQR: 10.4-22.1]; Child-Pugh B: 20.2 ug/mL [|QR: 15.1-25.9]; Child-Pugh C: 19.3 ug/mL [IQR: 14.9-25.2, P = .08]. The median vancomycin dose using the Kullar nomogram would have been 3.0 g/day (IQR: 2.0-3.75, P < .001), but the median dose actually used in this patient population was significantly less at 2.0 g/day. Nonetheless, the median vancomycin trough concentration in the entire patient population was 19.8 ug/mL (IQR: 15.4-25.9). Conclusion: In patients with cirrhosis, there was a high incidence of supratherapeutic vancomycin serum concentrations despite the fact that dosing was significantly less than that suggested by the published Kullar nomogram.
机译:背景技术:减少肝素前体的肝脏肝脏肝硬化患者的肝脏生产导致错误低血清肌酐值。因此,当进行万古霉素的经验剂量时,肌肉素间隙的高估可能导致辛艾米霉素水平明显,并且增加肾毒性的风险。目的:该研究的目的是评估儿童-PUGH评分分层肝硬化患者的万古霉素给药要求,随后与先前公布和经过验证的Kullar Rommogup中推荐的剂量进行比较。方法:对肝硬化患者的回顾性评估,肝硬化患者至少3次,患有至少3天的血清素,并且至少吸收了血清浓度。 Vancomycin每日剂量和相应的血清浓度与被儿童PUGH得分分层的患者收集。每位患者与发表的NOM图所示的剂量相比,他们的万古霉素剂量。结果:遵循共有的2011次课程。 Child-Pugh队列与初始万古霉素给药没有显着差异。 3个队列(Child-PUGH A:13.7 UG / ML [indquarlile范围,IQR:10.4-22.1]; Child-Pugh B:20.2ug / ml [| QR之间的中位数:15.1-25.9]; Child-PUGH C:19.3 UG / ML [IQR:14.9-25.2,P = .08]。使用Kullar NOM图的中位万霉素剂量将是3.0克/天(IQR:2.0-3.75, P <.001),但实际用于该患者群体中的中位数剂量在2.0克/天中显着较低。尽管如此,整个患者人口中的中位万霉素槽浓度为19.8ug / ml(IQR:15.4-25.9)。结论:在肝硬化患者中,尽管给药量显着低于公布的Kullar NOM图所示,但患有肝硬化的血清血清浓度的发病率很高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号